Platelet activation is not only an essential component of primary hemostasis but also plays a critical role in disease progression during sepsis. Sepsis involves inflammatory processes through releasing of several inflammatory mediators, such as interleukin (IL)-1β, IL-8, monocyte chemotactic protein 1, and tumor necrosis factor alpha [1] , and then influences microvascular thrombosis formation and both innate and adaptive immunity [2] . Thus, attenuation of platelet activation is suggested to be one possible treatment option for sepsis in preclinical studies [1] . Some retrospective observational studies have also revealed that prehospital antiplatelet use was associated with decreased mortality rate in sepsis patients [3] [4] [5] [6] , but there is still a place for argument until studies provide strong evidence to support whether antiplatelet drugs are a possible adjuvant treatment choice in sepsis (Table 1) .
In a recent article in Intensive Care Medicine, Dr. Wiewel and colleagues introduced a prospective observational cohort study to determine the association between pre-existing antiplatelet treatment and outcome of sepsis [16] . This study enrolled patients with strict diagnostic criteria of sepsis and reported that chronic antiplatelet treatment was not associated with the development of organ failure or shock during intensive care unit (ICU) stay or mortality after admission. It also disclosed no differences in 19 biomarkers between antiplatelet users and non-users during ICU stay. Although the robustness of this study is strengthened by well-defined sepsis diagnosis and documentation of relevant molecular biomarkers as an indicator of host immune response during sepsis, several concerns should be clarified.
First, in the study by Wiewel et al. [16] , the size of only 150 patients per group who remained after propensity score matching is too small relative to the expected size of population (>2000) to detect differences in both groups. The definite impact (neutral, harm, or benefit) of antiplatelet agents on sepsis may not be determined thoroughly in this study because it is underpowered. This is not the only negative report with the same concern about inadequate sample size. Valerio-Rojas et al. [8] investigated 651 sepsis patients with similar study design and reported insignificant association between antiplatelet treatment and mortality. However, they also addressed the limitation and concern about inadequate patient number and power. With an eye toward improving reliability, the number of patients should be expanded to reach sufficient power in the further studies.
Second, given lack of details of antiplatelet prescription (dose and duration) and unknown baseline biomarker levels prior to antiplatelet drugs, we could not exclude that this flaw may elicit an unexpected finding of insignificant difference of 19 biomarkers between antiplatelet users and non-users with sepsis, possibly as a result of antiplatelet drug resistance or inappropriate dosing. Besides, there are more than 170 different putative biomarkers linked to sepsis, but most of them serve as predictors rather than as therapeutic guidance [17] . Those biomarkers that were reported to be associated with aspirin administration in sepsis, such as inhibition of nuclear factor kappa B [18] , production of nitric oxide, and production of lipoxin [7, 10] , were not investigated by the current study. The lack of difference in 19 currently used biomarkers between antiplatelet users and non-users may therefore not represent a lack of benefit.
Moreover, the lack of data regarding timing of antiplatelet administration or discontinuation does not allow the authors to address the effect of these potential confounding variables on the outcomes. As we know, the inhibitory effect of aspirin or clopidogrel on platelet activation could last for about 1 week despite discontinuing these agents [12, 11] . Our previous registry study also found that the benefit of prehospital use of antiplatelet drugs on sepsis outcomes was strongest in current users followed by recent users [3] . However, in the current study, the use of antiplatelet agents before enrollment was not clear. Besides, possible receipt of antiplatelet agents after ICU admission in non-antiplatelet users wound tend to bias the results to the null. Furthermore, only less than 50 % of patients still had the antiplatelet drugs in the first 2 days of ICU admission. Therefore, early discontinuation of antiplatelet drugs prior to sepsis onset could also partially explain the neutral association in this study.
Although there are some limitations, this prospective observational cohort study introduced by Dr. Wiewel and colleagues is still very valuable. It is the first prospective study in this field and enrolled sepsis patients according to well-defined clinical evidence rather than database or chart review. It also performed meticulous propensity matching, including disease severity by APACHE score, SOFA score, organ failure, and shock, which is lacking in most previous investigations and may causing significant confounding.
Given the conflicting results and inherent limitations from observational studies, only randomized controlled trials aimed at exploring the potential roles of antiplatelet agents as adjuvant treatment in sepsis or preventive agents to reduce disease severity will integrate the best evidence into clinical care of sepsis patients. There are currently at least two ongoing relevant clinical trials. The first trial is "Aspirin for the Treatment of Sepsis" (NCT01784159) which will investigate the beneficial effect of aspirin treatment for 7 days on organ dysfunction and duration of ventilation in severe sepsis patients. Another one is "Aspirin to Inhibit Sepsis" (ANTISEPSIS, ACTRN12613000349741) which will assess the effect of daily aspirin treatment on the mortality and admission to ICU for sepsis. Overall, we suggest that clinicians must be cautious in prescribing routine prophylactic antiplatelet drugs for sepsis prevention of treatment in view of further cost-effectiveness and harm-benefit analyses with hard evidence.
